Related Experiment Video
Updated: Jun 11, 2025
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Temporal Dynamics of Oxidative Stress and Inflammation in Bronchopulmonary Dysplasia
Michelle Teng1,2, Tzong-Jin Wu1,2, Xigang Jing1,2
1Department of Pediatrics, Medical College of Wisconsin, Suite C410, Children Corporate Center, 999N 92nd Street, Milwaukee, WI 53226, USA.
Insights
A novel agent, N-acetyl-lysyltyrosylcysteine amide (KYC), shows promise in treating bronchopulmonary dysplasia (BPD), a common lung issue in premature infants. This new therapy targets oxidative stress and inflammation, offering a potential breakthrough for BPD treatment.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is the most frequent lung complication in premature infants, with limited understanding of its pathophysiology and stable prevalence.
- Oxidative stress and inflammation are key factors in BPD development, closely linked to premature birth, and their interplay is critical for new therapeutic strategies.
- Current treatments targeting only antioxidants or anti-inflammatories have limited success, highlighting the need for novel therapeutic agents.
Purpose of the Study:
- To investigate the efficacy of a novel tripeptide, N-acetyl-lysyltyrosylcysteine amide (KYC), as a potential treatment for bronchopulmonary dysplasia (BPD).
- To explore the mechanisms by which KYC may alleviate BPD, including its effects on myeloperoxidase (MPO), oxidative stress, endoplasmic reticulum stress, and cellular senescence.
Main Methods:
- Utilized a hyperoxia rat model to simulate conditions leading to BPD.
- Administered KYC, a reversible myeloperoxidase inhibitor and systems pharmacology agent, to assess its impact on BPD severity.
- Evaluated KYC's effects on key pathological markers including MPO activity, antioxidative proteins, endoplasmic reticulum stress, and cellular senescence.
Main Results:
- KYC demonstrated a reduction in BPD severity in the hyperoxia rat model.
- The therapeutic effects of KYC were associated with MPO inhibition, enhancement of antioxidative proteins, and alleviation of endoplasmic reticulum stress and cellular senescence.
- These findings suggest a multi-faceted mechanism of action for KYC in mitigating BPD pathology.
Conclusions:
- N-acetyl-lysyltyrosylcysteine amide (KYC) represents a promising novel therapeutic agent for bronchopulmonary dysplasia (BPD).
- KYC's ability to inhibit MPO, boost antioxidant defenses, and reduce cellular stress provides a new avenue for treating this common prematurity complication.
- Further research into KYC could lead to improved clinical outcomes for infants suffering from BPD.
Abstract:
Bronchopulmonary dysplasia (BPD) is the most common lung complication of prematurity. Despite extensive research, our understanding of its pathophysiology remains limited, as reflected by the stable prevalence of BPD. Prematurity is the primary risk factor for BPD, with oxidative stress (OS) and inflammation playing significant roles and being closely linked to premature birth. Understanding the interplay and temporal relationship between OS and inflammation is crucial for developing new treatments for BPD. Animal studies suggest that OS and inflammation can exacerbate each other. Clinical trials focusing solely on antioxidants or anti-inflammatory therapies have been unsuccessful. In contrast, vitamin A and caffeine, with antioxidant and anti-inflammatory properties, have shown some efficacy, reducing BPD by about 10%. However, more than one-third of very preterm infants still suffer from BPD. New therapeutic agents are needed. A novel tripeptide, N-acetyl-lysyltyrosylcysteine amide (KYC), is a reversible myeloperoxidase inhibitor and a systems pharmacology agent. It reduces BPD severity by inhibiting MPO, enhancing antioxidative proteins, and alleviating endoplasmic reticulum stress and cellular senescence in a hyperoxia rat model. KYC represents a promising new approach to BPD treatment.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:17Pulmonary Cycle: Exhalation
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: